From: Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas
Clinicopathologic characteristics | mTOR+ | mTOR- | P | p-mTOR+ | p-mTOR - | P |
---|---|---|---|---|---|---|
n(%) | n(%) | n(%) | n(%) | |||
Triple negative | 22 (42.31%) | 9 (17.31%) | 0.03 | 24 (41.38%) | 7 (12.07%) | 0.0005 |
Non-triple negative | 11 (21.15%) | 16 (30.77%) | 8 (13.79%) | 19 (32.76%) | ||
Total | 33 | 25 | 32 | 26 | ||
mTOR + | 24 (41.38%) | 8 (13.79%) | 0.0032 | |||
mTOR - | 9 (17.31%) | 17 (29.31%) | ||||
32 | 26 | |||||
* | *** | |||||
HER2 + | 7 (12.07%) | 12 (20.69%) | 0.0479 | 4 (6.9%) | 15 (25.86%) | 0.0005 |
HER2 - | 26 (44.83%) | 13 (22.41%) | 28 (48.28%) | 11 (18.97%) | ||
Total | 33 | 25 | 32 | 26 | ||
>1 cm | 27 (46.55%) | 16 (27.59%) | >0.05 | 22 (42.31%) | 20 (30.48%) | 0.05 |
≤1 cm | 8 (13.79%) | 7 (12.07%) | 10 (17.24%) | 6 (10.34%) | ||
35 | 23 | 32 | 26 | |||
Grade I | 5 (8.62%) | 4 (6.90%) | >0.05 | 4 (6.90%) | 5 (8.62%) | >0.05 |
Grade II | 12 (20.69%) | 12 (20.69%) | 14 (24.14%) | 10 (17.24%) | ||
Grade III | 16 (27.59%) | 9 (15.52%) | 14 (24.14%) | 11 (21.15%) | ||
Total | 33 | 25 | 32 | 26 | ||
Vascular invasion | 7 (12.07%) | 7 (12.07%) | >0.05 | 6 (10.34%) | 8 (13.79%) | >0.05 |
No vascular invasion | 26 (44.83%) | 18 (31.03%) | 26 (44.83%) | 18 (31.03) | ||
Total | 33 | 25 | 32 | 26 | ||
Relapsed | 25 (43.10%) | 20 (30.48%) | >0.05 | 17 (29.31%) | 28 (48.28%) | >0.05 |
Not relapsed | 8 (13.79%) | 5 (8.62%) | 7 (12.07%) | 6 (10.34%) | ||
Total | 33 | 25 | 24 | 34 | ||
Relapsed 0–6 months | 17 (37.78%) | 14 (31.11%) | >0.05 | 9 (20.00%) | 22 (48.89%) | >0.05 |
Relapsed 6–12 months | 4 (8.89%) | 3 (31.03%) | 4 (8.89%) | 3 (31.03%) | ||
Relapsed >12 months | 4 (8.89%) | 3 (31.03%) | 4 (8.89%) | 4 (31.03%) | ||
Total | 25 | 20 | 17 | 28 | ||
Mitotic indexa 1 | 4 (6.90%) | 2 (3.45%) | >0.05 | 3 (5.17%) | 3 (5.17%) | >0.05 |
Mitotic index 2 | 7 (12.07%) | 8 (13.79%) | 8 (13.79%) | 7 (12.07%) | ||
Mitotic index 3 | 22 (42.31%) | 15 (25.86%) | 21 (36.21%) | 16 (27.59%) | ||
Total | 33 | 25 | 32 | 26 |